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Abstract 
Objective: Reports correlating total 
homocysteine (tHcy) concentrations with 
arteriosclerosis have become a matter of interest 
amongst healthcare professionals and the public. 
Several commercial preparations of vitamin B 
complexes have been marketed as supplements 
intended to reduce elevated levels of tHcy. 
Among these preparations are those that have 
been specifically designed for sublingual 
administration. This study is designed to evaluate 
the relative efficacy of sublingually vs. orally 
delivered vitamin B complex in reducing serum 
tHcy levels. 
Design: Forty-one subjects, between the ages of 
50-80 years with total serum tHcy concentrations 
exceeding 11 µmol/l, were treated with a six-
week regimen of vitamin B complex. Each B 
complex consisted of 1000 µg vitamin B12 (as 
methylcobalamin), 400 µg folate (as folic acid), 
and 5 mg vitamin B6 (as pyridoxine HCl). 
Participants in the study were randomized into 
two groups designated, retrospectively, as SL 
and PO. Members of the group SL were given a 
sublingually delivered vitamin B complex and a 
matching orally delivered placebo. Members of 
group PO were given a orally delivered vitamin 
complex and a matching sublingually delivered 
placebo. A statistically significant reduction in 
tHcy values was observed in both groups upon 
completion of the six-week protocol. 
Materials and Methods 
Protocol:  
 
Inclusion criteria: 
 
• must sign an informed consent form 
• must be between the ages of 50-80 years 
• must have a fasting serum tHcy level greater 
than or equal to 11 µmol/l 
 
Exclusion criteria: 
• must have a fasting serum tHcy level 
• greater than or equal to 11 µmol/l 
• serum tHcy level is < 11 µmol/l  
• is pregnant or breast feeding  
• has had surgery within 30 days  
• has had a myocardial infarction  
• has unstable angina  
• has had a stroke within the last 6 months 
• has clinically overt peripheral vascular disease 
• has been diagnosed or demonstrates 
symptoms  
• consistent with congestive heart failure  
• is receiving any heart disease related 
medication  
• started less than three months prior to the 
study 
 SL Group PO Group Between P Value 
Baseline tHcy 14.0 ± 2.6 13.7 ± 2.0         NS 
6 Weeks tHcy  8.9 ± 1.6  8.7 ± 2.1         NS 
Within P value  P < 0.05  P < 0.05  
    
Table #1. tHcy concentrations of groups before and after treatment. tHcy values 
are expressed in µmol/l  and displayed as mean ± SD. NS = Not Significant. 
Conclusions: The efficacy of vitamin B complex 
therapy used in the treatment of 
hyperhomocysteinemia is well established. The 
purpose of this study was to assess treatment 
dependence on the route of administration by 
comparing reductions in serum tHcy in subjects 
given vitamin complex orally to those given the 
same complex sublingually. When a vitamin 
complex preparation, consisting of 1000 µg 
vitamin B12 (as methylcobalamin), 400 µg folate 
(as folic acid), and 5 mg vitamin B6 (as 
pyridoxine HCl), was administered to subjects 
using oral and sublingual routes of 
administration, no difference in effect following a 
six-week treatment period was observed in 
middle-aged to elderly subjects with 
hyperhomocysteinemia who were otherwise 
healthy. 
Results 
Figure 1.  Total serum homocysteine 
concentrations of six subjects plotted 
as a function of time. Solid line: 
Average of PO group (squares), 
Dotted line: Average of SL group 
(circles). ….  SL Group, __   PO 
Group. 
Results: The dropout rate was 2.4% (1/42). The 
SL and PO groups were assigned a total of 20 
and 21 subjects, respectively. There were no 
significant differences between the two groups 
with respect to gender distribution, mean age, or 
compliance. Mean serum tHcy concentrations of 
subjects before and after treatment are listed in 
Table 1. A statistically significant reduction in 
tHcy values was observed in both groups upon 
completion of the six-week protocol.  There was 
no statistically significant difference in serum 
tHcy concentrations between groups either 
before or after treatment. 
 
The serum tHcy concentrations of three subjects 
from the SL group and three subjects from the 
PO group were measured weekly. In both 
groups, the most significant decline in tHcy 
concentrations occurred during the first three to 
four weeks of therapy with changes in levels 
thereafter becoming asymptotical.  Serum tHcy 
concentrations are plotted as a function of time in 
Figure 1. 
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